Weekly Recap | Invivyd -12%, VYD2311 accelerated approval in focusWeekly Review·Oct 3, 2026 at 07:05 AMIVVD+0.54%
Weekly Recap | Invivyd +23.69%, most brokers rate it buyWeekly Review·Sep 26, 2026 at 06:32 AMIVVD+0.54%
The Nasdaq Biotechnology Index fell by more than 1.2%. Among them, Medpace dropped 15.90%, Tectonic Therapeutic fell 15.22%, Regenxbio decreased 14.31%, Humacyte declined 13.93%, and Anavex Life Sciences fell 8.74%. In contrast, Mesoblast rose 7.21%, Personalis increased 10.03%, Invivyd gained 10.14%, PepGen surged 17.99%, and Neumora Therapeutics jumped 25.10%Wallstreetcn·Feb 10, 2026 at 11:10 PMIDNA-0.32%RGNX-6.83%
